Vera Therapeutics, Inc.
27.99USD
-1.0600 (-3.65%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on VERA.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | — | — | — | — | 24.8M | 233.8M |
| Q1 | — | — | — | — | — | — |
| Q2 | — | — | — | — | — | — |
| Q3 | — | — | — | — | 3.7M | — |
| Q4 | — | — | — | — | 17.4M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -3.35 | -2.25 | -2.75 | -4.66 | -6.25 | -4.25 |
| Q1 | -.710 | -.800 | -.560 | -.810 | -1.69 | — |
| Q2 | -.550 | -.460 | -.620 | -1.20 | -1.52 | — |
| Q3 | -.910 | -.450 | -.850 | -1.26 | -1.61 | — |
| Q4 | -1.22* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -.601* |
| -.785* |
| -1.42* |
| -1.54 |
| — |
Debt level and coverage